Cancer BiologybioRxivPreprint
Lymphoma response to chimeric antigen receptor T cell therapy is driven by endogenous tumor-reactive CD8⁺ T cells
Bachisio Ziccheddu, Constanza Savid-Frontera, Venu V.G. Saralamma…·Frederick Lundry Locke
This study shows that durable CAR-T therapy in lymphoma requires cooperation with endogenous CD8 T cells, and tumors lacking MHC class I or CD58 resist treatment.
DOI 10.64898/2026.10.23.761341